Application of adipose-derived stem cells combined with platelet-poor plasma in acceleration of orthodontic tooth movement and bone reconstruction
By injecting a combination of adipose-derived stem cells and anemic platelet-rich plasma into the periodontal ligament during orthodontic treatment, the problems of slow tooth movement and bone loss are solved, resulting in faster tooth movement and increased bone mass, while reducing trauma and side effects.
Patent Information
- Application Number
- CN202310607936.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-26
- Publication Date
- 2024-11-26
AI Technical Summary
Current orthodontic treatments often result in slow tooth movement and significant bone loss. Traditional methods, such as cortical osteotomy, are highly invasive, have numerous side effects, and are poorly accepted by patients.
A combination of adipose-derived stem cells (ADSCs) with platelet-poor plasma (PPP), platelet-rich plasma (PRP), or platelet lysate (PL) is injected into the periodontal ligament to promote tooth movement and bone remodeling.
It accelerates tooth movement, increases bone mass, reduces bone loss, minimizes trauma, and improves treatment effectiveness and patient acceptance.
Smart Images

Figure CN119015313A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and mainly relates to the use of adipose stem cells combined with platelet-poor plasma in accelerating orthodontic tooth movement and bone remodeling. Background Art
[0002] With the improvement of living standards and the continuous increase in aesthetic needs, adult orthodontics has become more and more popular. Compared with young patients, the orthodontic treatment process for adult patients is usually more complicated. Not only the treatment cycle may last for 2-3 years or even longer, but more and more patients are asking for a shorter treatment time. At the same time, doctors have to face the complications that occur during long-term correction, including caries, periodontitis, root resorption, and bone loss. There is an urgent need for a method that can accelerate the speed of orthodontic tooth movement (OTM), slow down bone loss, and even increase bone mass, so that correction can be suitable for a larger population. At present, the method of accelerating orthodontic tooth movement and increasing bone mass is mainly to perform bone grafting at the same time as cortical bone incision, which can effectively promote bone healing in the surgical area and improve the condition of periodontal soft and hard tissues, that is, periodontally accelerated osteogenic orthodontics (PAOO).
[0003] Some case reports reflect the side effects of PAOO, especially the effects of cortical bone cutting on periodontal tissues, mainly including mild loss of alveolar bone height between teeth, loss of attached gingiva, and even defects in periodontal tissues at sites with close interdental distances, or subcutaneous hematomas on the face and neck. In addition, the operation requires flap opening and cortical bone splitting, which is very traumatic and has low patient acceptance. Based on this, it is necessary to explore minimally invasive, postoperatively reactive, and effective methods to accelerate orthodontic tooth movement and promote osteogenesis. Summary of the invention
[0004] To solve the above technical problems, the present invention provides a composition of adipose-derived stem cells (ADSCs) and platelet-poor plasma (PPP), or a composition of adipose-derived stem cells (ADSCs) and platelet-rich plasma (PRP), or a composition of adipose-derived stem cells (ADSCs) and platelet lysate (PL) for preparing a medicament for accelerating orthodontic tooth movement and bone remodeling.
[0005] According to an embodiment of the present invention, the adipose stem cells are human adipose stem cells, canine adipose stem cells or mouse adipose stem cells, such as human subcutaneous tissue adipose stem cells, intraperitoneal region adipose stem cells and organ surface adipose stem cells.
[0006] According to an embodiment of the present invention, the platelet-poor plasma is human platelet-poor plasma or rat platelet-poor plasma.
[0007] According to an embodiment of the present invention, the platelet-rich plasma is human platelet-rich plasma or rat platelet-rich plasma.
[0008] According to an embodiment of the present invention, the platelet lysate is human platelet lysate or rat platelet lysate.
[0009] According to an embodiment of the present invention, the composition further comprises a pharmaceutically acceptable carrier or excipient; the pharmaceutically acceptable carrier or excipient is selected from at least one of the following: glycerol, sorbitol, sodium carboxymethyl cellulose, xanthan gum, carrageenan, polyethylene glycol, sodium pyrophosphate, sodium lauryl sulfate, allantoin, sodium saccharin, sodium benzoate, ethyl paraben, calcium carbonate, calcium hydrogen phosphate dihydrate, calcium hydrogen phosphate anhydrous, silicon dioxide, hydroxyapatite, dipotassium glycyrrhizinate, and flavor.
[0010] According to an embodiment of the present invention, the composition is an injection preparation.
[0011] According to an embodiment of the present invention, the composition is adipose stem cell osteogenic differentiation medium and PPP.
[0012] According to an embodiment of the present invention, the injection preparation is prepared by resuspending ADSCs by PPP, PRP or PL.
[0013] According to an embodiment of the present invention, each 0.3 ml of PPP, PRP or PL contains 1×10 5 ~1x10 7 ADSCs, e.g. 1x10 6 ~7x10 6 ADSCs, preferably 3x10 6 ADSCs.
[0014] The present invention also provides a method for accelerating orthodontic tooth movement and bone remodeling, comprising administering a composition of adipose stem cells and platelet-poor plasma, or a composition of adipose stem cells (ADSCs) and platelet-rich plasma (PPP), or a composition of adipose stem cells (ADSCs) and platelet lysate (PL) to a subject in need thereof.
[0015] In one embodiment, the subject is a human.
[0016] According to an embodiment of the present invention, when the subject is a human, the injection point is within the periodontal ligament; and the injection time is once a week.
[0017] Beneficial Effects
[0018] The present invention injects PPP combined with ADSCs into the periodontal ligament in the area of orthodontic force tooth movement for the first time, and finds that compared with the OTM group, OTM+PPP group, and OTM+ADSCs group, the CEJ-ABC height is reduced, the trabecular gap is reduced, the number of trabeculae, trabecular thickness, and bone volume fraction increase or even exceed the CON group, indicating that PPP combined with ADSCs can more effectively promote alveolar bone osteogenesis, increase bone mass, and even restore the bone mass level before tooth movement. HE staining results show that a large amount of new bone is formed and the periodontal fiber morphology is restored. Trap staining results show that the number of osteoclasts is the highest. This result is consistent with the highest expression of immunohistochemistry OPG. At the same time, RANKL expression also reaches the highest or even exceeds OPG expression, indicating that PPP combined with ADSCs injection significantly activates bone metabolism and promotes osteoblast proliferation. The treatment method of the present invention provides new ideas and theories for clinically expanding the range of orthodontic tooth movement, movement speed, and healthy and stable periodontal tissue after correction.
[0019] Terms and Definitions
[0020] The platelet-poor plasma (PPP) described in the present invention is a plasma product with a platelet concentration lower than the baseline level in whole blood. For example, the average platelet content in the platelet-poor plasma used in the embodiments of the present invention is 79x10 9 / L, the number of red blood cells is 0.0 / L, and the number of white blood cells is 0.0 / L. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 The morphological observation results of rat adipose stem cells (magnification: x100, scale bar = 50 μm).
[0022] Figure 2 Identification of multidirectional differentiation of rat adipose-derived stem cells.
[0023] Figure 3 Comparison of the osteogenic capacity of rat adipose-derived stem cells combined with platelet-poor plasma (Alizarin red staining, magnification: x200, scale bar = 50 μm).
[0024] Figure 4 A force-applied orthodontic tooth model for the left maxillary side of rats was constructed (a: a force-applied orthodontic tooth model for the left maxillary side of rats, b: the mesial movement of the first molar after the force-applied device was removed 4 weeks after the force-applied device was removed, c: the mesial movement of the first molar after the force-applied device was removed 8 weeks after the force-applied device was removed).
[0025] Figure 5 Impressions were taken from the rat maxilla (a: impression taking, b: impression completion, c: hard plaster model).
[0026] Figure 6 The tooth movement distance was measured for the model palatal mucosal overlap.
[0027] Figure 7 Micro-CT scanning analysis images (a: measuring the CEJ-ABC heights at three locations on the buccal side of the mesial root of the first molar, b: selecting a 0.5 mm diameter area at the level of the ROI root bifurcation, c: selecting a 1 mm diameter area at the ROI level along the apical direction at 1 mm height).
[0028] Figure 8 These are photos of the samples after 8 weeks of decalcification.
[0029] Fig. 9 The results of tooth movement distance detection in different groups at different times [lowercase letters represent statistical differences at different times within the same group, and uppercase letters represent statistical differences at the same time between groups (P<0.05)].
[0030] Fig.10 Micro-CT scanning results of alveolar bone height in different groups (a: three-dimensional reconstruction and two-dimensional screenshot of alveolar bone after force application; b: measurement results of CEJ-ABC distance of alveolar bone *: P < 0.05, **: P < 0.01, ***: P < 0.005).
[0031] Fig.11 Micro-CT scanning results of alveolar bone parameters in different groups (*: P < 0.05, **: P < 0.01, ***: P < 0.005).
[0032] Fig.12 HE staining was used to observe tissue morphology and Trap-stained osteoclast counts (a: HE staining results, magnification: x400, scale bar = 50 μm, b: Trap staining results, magnification: x400, scale bar = 50 μm, c: Trap-stained osteoclast counts, *: P < 0.05, **: P < 0.01, ***: P < 0.005).
[0033] Fig.13 These are the results of RANKL and OPG immunohistochemistry (a: RANKL immunohistochemistry results, magnification: x400, scale bar = 50 μm, b: OPG immunohistochemistry results, magnification: x400, scale bar = 50 μm, c: average optical density results of RANKL, OPG, and RANKL / OPG ratio, *: P < 0.05, **: P < 0.01, ***: P < 0.005). DETAILED DESCRIPTION
[0034] The technical scheme of the present invention will be further described in detail below in conjunction with specific embodiments. It should be understood that the following embodiments are only exemplary descriptions and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope that the present invention is intended to protect.
[0035] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.
[0036] Preparation Example 1 Cultivation and Identification of Rat Adipose-Derived Stem Cells (ADSCs)
[0037] 1.1 Culture of rat adipose-derived stem cells
[0038] Four 8-week-old rats were selected as donors. Under local anesthesia (1% sodium pentobarbital, 4 ml / kg), the inner thigh fat was taken as the donor area. After the surrounding skin tissue was disinfected, a 1 cm 3 The tissue block was then repeatedly rinsed with phosphate buffered saline diluent, the blood vessels and fascia in the tissue block were removed and cut into 1mm pieces with small scissors. 3 Prepare 4 times the volume of fat blocks, 0.1% type I collagenase, treat in 37°C water for 45 minutes, add the same volume of penicillin to the culture medium, and centrifuge the digestion solution in a centrifuge at 1000r / min for 15 minutes to remove the suspended fat and clear liquid on the upper layer. Collect the precipitate after centrifugation, and take 15ml of the precipitate and suspend it again with 0.15ml NH4Cl, let it stand for 15 minutes. When the red blood cells are completely decomposed, centrifuge it again at 1500r / min, suspend the precipitate with culture medium, observe the activity of the cells under a microscope, and count the number of cells with a cell counting plate. Use serum-free cell culture medium containing 10% fetal bovine serum, culture in a 37°C, 5% CO2 incubator, change the culture medium every 2 days, and when the cell growth confluence reaches 90%, use 0.25% trypsin to digest and subculture, and culture to the third generation. The third-generation rat adipose stem cells were placed under an electron microscope for observation, and it can be seen that the cells are spindle-shaped, with complete morphology and good growth status ( Figure 1 ).
[0039] 1.2 Identification of the multidirectional differentiation ability of rat adipose-derived stem cells
[0040] The third generation ADSCs suspension was added to the osteogenic induction solution, and the solution was changed every 2 days. After the third day of culture, they were stained with Alizarin Red, observed and photographed under a microscope to identify their osteogenic differentiation ability; they were stained with Oil Red O, observed and photographed under a microscope to identify their adipogenic differentiation ability.
[0041] The third generation of rat adipose stem cells were induced to adipogenesis for 14 days, and the formation of lipid droplets stained red was observed by Oil Red 0 staining, indicating that they have adipogenic ability ( Figure 2 a); After 21 days of osteogenic induction of rat adipose-derived stem cells cultured to the third generation, red calcium nodules were formed by alizarin red staining, indicating that the cells have osteogenic capacity ( Figure 2b). Preparation Example 2: Extraction and Identification of Platelet-Poor Plasma (PPP)
[0042] 2.1 Extraction of platelet-poor plasma
[0043] Four 8-week-old rats were selected as donors. Under local anesthesia (1% sodium pentobarbital, 4 ml / kg), the cardiac vein was used as the blood collection area. After the surrounding skin tissue was disinfected, the chest cavity was opened to expose the heart. Four tubes of blood were collected using a 10 ml blood collection tube containing sodium citrate anticoagulant. The blood was centrifuged at 2000 r / min for 18 min. The liquid was divided into three layers, the lower layer was red blood cells, the middle layer was gel, and the upper layer was pale yellow plasma containing a small amount of platelets. The upper layer was drawn and centrifuged at 3200 r / min for 8 min. The upper clear liquid was taken to obtain PPP. PPP was packaged at 0.3 ml / tube and frozen at -80°C for later use.
[0044] 2.2 Identification of platelet-poor plasma
[0045] PPP is a plasma product with a platelet concentration lower than the baseline level in whole blood. Three 100-μl PPP samples and venous blood were taken, and the white blood cell, red blood cell and platelet count concentrations were analyzed by a blood routine analyzer. The experiment was repeated three times, and the platelet concentrations in PPP and venous blood were compared and calculated.
[0046] Take 0.3ml of extracted PPP and three portions of whole blood, and test them with an automatic blood cell analyzer (Mindray veterinary automatic blood cell analyzer model: BC-2800vet). The average platelet count in rat whole blood is 1739x10 9 / L, the number of red blood cells is 9.18x10 12 / L, white blood cell count is 9.0x10 9 / L, while the average platelet content in rat PPP after centrifugation was 79x10 9 / L, the number of red blood cells was 0.0 / L, and the number of white blood cells was 0.0 / L, which confirmed that the platelet concentration in PPP was significantly lower than that in whole blood, and the purity was significantly higher than that in whole blood, with statistical difference (P < 0.01).
[0047] Example 1
[0048] Take the third generation ADSCs and culture them at 2x10 4 cells / cm 2The cells were inoculated at a density of 100 μg / cm2 in a six-well plate, and 2 ml of serum-free cell culture medium containing 10% FBS was added to each well. The cells were divided into three groups: CON (blank control group), ADSCs (positive control group), and PPP+ADSCs (experimental group). The CON group was a serum-free cell culture medium containing 10% FBS; the ADSCs group was an adipose stem cell osteogenic differentiation medium; the PPP+ADSCs group was an adipose stem cell osteogenic differentiation medium containing 5% PPP (5 volumes of PPP working solution were added to 95 volumes of ADSCs solution and mixed thoroughly). There were 3 replicate wells in each group. When the cell fusion reached 60% to 70%, osteogenic induction was performed. The induction process was the same as in Preparation Example 1. After 14 days of induction, alizarin red staining was performed.
[0049] The results of alizarin red staining showed that the CON group had no calcium nodules and was not stained; a small amount of calcium nodules were visible in the ADSCs group, which was stained red and had osteogenic ability; the ADSCs+PPP group had more calcium nodules formed, which were stained red and had stronger osteogenic ability ( Figure 3 ).
[0050] Example 2
[0051] 2.1 Construction of the rat maxillary left orthodontic tooth force model (OTM)
[0052] After 1 week of adaptive feeding, 50 SD rats were anesthetized by intraperitoneal injection of 1% sodium pentobarbital (4 ml / kg), and the limbs of the rats were fixed. An orthodontic force tooth movement model was established on the left side of the rat maxilla.
[0053] Using a slow dental motor with a pointed diamond needle, under the premise of continuous cooling with 0.9% saline, a groove of about 0.5mm deep was ground on the cervical surface of the labial, lingual, and distal surfaces of the maxillary central incisors close to the gingival margin. The groove level on each surface was at the same level of the tooth surface. One end of the nickel-titanium spiral tension spring with stainless steel ligature wires at both ends was embedded in the groove to ligate the two incisors from the cervical surface as a whole; then the other end was passed between the first and second molars on the left side and wrapped around the first molar before ligation. In order to enhance the support and prevent the orthodontic device from falling off, the tooth surfaces of the two incisors were cleaned, etched with 25% phosphoric acid, rinsed and dried with a washing and blowing ball, and then the adhesive was applied. Transbond XT adhesive was further light-cured and bonded to the two central incisors ( Figure 4 a). The maxillary first molar was moved mesially with the two maxillary central incisors as support. The force of the coil spring was measured with an orthodontic dynamometer, and the force value was 30g.
[0054] 2.2 Group injection preparations
[0055] After the force-added model was constructed, each group was injected with a U-40 sterile insulin syringe. The injection site was in the buccal periodontal ligament of the left maxillary first molar, 2 mm below the cementoenamel junction. The corresponding preparations were injected according to the groups, with an injection volume of 0.3 ml. The ADSCs+PPP group was injected with 0.3 ml containing 3x10 6 PPP of ADSCs, the cell content of ADSCs group was also 3x10 6 , PPP group was 0.30 ml of PPP prepared in the above Preparation Example 2. The mucosa was disinfected with iodine tincture, and the injection needle was placed close to the buccal surface of the mesial root of the first molar, 2 mm below the cementoenamel junction, and the needle was inserted at an angle of 20° until the needle reached the bone surface. The injection interval was once a week.
[0056] In addition, a blank group (CON group) and a rat maxillary left orthodontic tooth force model group (OTM group) were set up.
[0057] The blank control group was filled with normal saline, and the cell group was filled with culture medium after trypsin digestion.
[0058] 2.3 Tooth movement distance measurement
[0059] 2.3.1 Taking the model at different time points
[0060] The cardboard was cut into a 4cmx3cm rectangle and used as a tray for rat impression. A low-speed ball drill was used to drill more than ten small holes in the cardboard to increase retention and prevent the alginate impression material from falling off. The rats in each group were anesthetized on the 0th, 3rd, 7th, and 14th days after the model was constructed. After the mandible was pulled open, the alginate impression material was loaded on the tray and placed in the rat's upper palate and removed after 30 seconds ( Figure 5 a). Note that you need to lift your tongue during the process to avoid suffocation due to airway obstruction. Immediately after the mold is taken, use hard plaster to pour into the model ( Figure 5 b, c).
[0061] 2.3.2 Model scanning overlap measurement of tooth movement distance
[0062] After trimming the model, it was scanned using itero (Invisalign, USA). The stl file was downloaded from My itreo.com and then imported into Geomagic studio 2014 (USA) for measurement. The model of day 0 was imported and overlapped with the models of days 3, 7, and 14 using the maxillary palatal mucosa. After automatic calibration, the line connecting the buccal mesial edge of the first molar and the midpoint of the lingual gingival margin of the two upper incisors was used as the measurement value ( Figure 6 ). Tooth movement distance = 0 day measurement value - n day measurement value.
[0063] 2.4 Alveolar bone osteogenesis detection
[0064] 2.4.1 Micro-CT scanning analysis
[0065] At 4 and 8 weeks after injection, rats (n=6) were euthanized by carbon dioxide, and the left maxillary bone was separated so that the teeth on the experimental side were facing upward and the mesiodistal cusp line of the first molar was fixed parallel to the ground. Micro-CT scanning (Skyscan Bruker, Germany) was performed, and the scanning parameters were set as follows: voltage 70 kV, current 200 uA, pixel size 20.25 μm.
[0066] The 3D structure was reconstructed using CTvox software (Bruker, Germany), and the CEJ-ABC heights at three locations on the buccal side of the mesial root of the first molar were measured using DataViewer software (Bruker, Germany). Figure 7 a), rotate and adjust the scanned image: sagittal first molar and third molar connecting line level, coronal first molar buccal and lingual level, horizontal crown to root are visible, save the adjusted image and import it into CTAn software (Bruker, Germany), select a 0.5mm diameter area from the level of the mesiobuccal root and distal buccal root bifurcation ( Figure 7 b), select a 1mm diameter area at a height of 1mm along the apical direction ( Figure 7 c), that is, the truncated cone-shaped column in the alveolar septum was taken as the region of interest (ROI), and the relevant structural parameters of the alveolar bone, such as bone volume fraction (BV / TV), trabecular thickness (Tb.N), trabecular thickness (Tb.Th), and trabecular separation (Tb.Sp), were measured and analyzed.
[0067] 2.4.2 HE staining to observe tissue morphology in the applied area
[0068] After Micro-CT scanning, the left first molar and periodontal tissue were obtained, fixed with 4% paraformaldehyde (n=6), and decalcified with 10% EDTA for 8 weeks ( Figure 8 ), embedded in paraffin along the mesiodistal part of the first molar, pre-sectioned with a microtome to ensure that the mesiodistal root of the first molar and the mesial root of the second molar were present, serial sections with a thickness of 4 μm were made, the sections were dewaxed to water, stained with hematoxylin, washed with water, dehydrated with gradient ethanol, stained with eosin, and scanned with an electron microscope to collect images, and the tissue morphology of the mesial root of the first molar in the force application area was observed.
[0069] 2.4.3 Trap staining to detect osteoclast count
[0070] The sections were prepared as above according to the instructions of the Trap staining solution set, the sections were dewaxed and hydrated, the cell nuclei were counterstained, the sections were sealed, and the sections were scanned by electron microscope. The images were collected and analyzed using Image-Pro Plus 6.0 software (Media Cybernetics, USA). All the slides were read in a double-blind manner.
[0071] 2.4.4 Immunohistochemical detection of RANKL and OPG bone-related proteins
[0072] Paraffin sections were dewaxed to water, and after antigen repair, endogenous peroxidase was blocked, serum was blocked, and primary antibodies were added, with a ratio of RANKL (1:100) and OPG (1:200). Secondary antibodies (HRP labeled) of the corresponding species of the primary antibodies were added to cover the tissue, DAB was used for color development, hematoxylin was used for counterstaining, dehydrated and sealed, and electron microscope scanning was performed to collect images. Histochemical results showed that hematoxylin stained the cell nucleus in blue, and DBA showed positive expression in brown-yellow. Analysis of immunohistochemical staining: Five fields of view were randomly selected from each section, and the average integrated optical density (IOD) of the staining was analyzed using Image-Pro Plus 6.0 software. All slides were read in a double-blind manner.
[0073] 2.5 Statistical analysis
[0074] The above experimental results are expressed as mean ± standard deviation, and the results are analyzed using SPSS 26.0 statistical analysis software. One-way analysis of variance (ANOVA) was used to compare data between different groups, and Tukey's post hoc test was used to compare data between two groups. P < 0.05 indicated statistical significance.
[0075] 2.6 Results Analysis
[0076] 2.6.1 Model overlap measurement of tooth movement distance
[0077] Except for the CON group, the tooth movement distances of the other groups gradually increased on days 0, 3, 7, and 14. The tooth movement rate of the OTM and ADSCs groups was the highest on day 7, while the tooth movement rate of the PPP group and the ADSCs+PPP group was the highest on day 14, and the difference was statistically significant (P < 0.05). Compared with the OTM group, there was no statistical difference in the tooth movement distance of the OTM+ADSCs group, while the tooth movement distance of the OTM+PPP group was the highest, followed by the OTM+ADSCs+PPP group, and the difference was statistically significant (P < 0.05) ( Fig. 9 ).
[0078] 2.6.2 Micro-CT scanning alveolar bone height detection results
[0079] At 4 and 8 weeks after injection, Micro-CT scanning analysis showed that compared with the CON group, the buccal alveolar bone height from the first molar to the third molar in the other groups was reduced, and the tooth roots were exposed. It was also found that when the first molar moved forward mesially, the second molar would move mesially spontaneously, and the second molar in the OTM+PPP group, OTM+ADSDs group, and OTM+ADSCs+PPP group had a larger mesial movement range than the OTM group, and there was even no gap between the second molar and the first molar ( Figure 4 b, c, Fig.10 a). At 4 weeks and 8 weeks after injection, the CEJ-ABC distances of the CON group were 0.45±0.01mm and 0.61±0.04mm, respectively. The CEJ-ABC distances of all groups were increased compared with the CON group (P<0.005). However, at 4 weeks after injection, except for the CON group, the CEJ-ABC distance of the OTM group was the highest, which was 1.05±0.02mm, followed by the OTM+PPP group and the OTM+ADSDs group. The CEJ-ABC distance of the OTM+ADSCs+PPP group was the lowest, which was 0.87±0.01mm, with statistically significant differences (P<0.05). At 8 weeks after injection, except for the CON group, the CEJ-ABC distance in the OTM+PPP group was the highest at 1.28±0.06mm, followed by the OTM group, with no statistical difference between the two groups, and the OTM+ADSCs group, with a statistical difference (P<0.01), but there was no statistical difference between it and the lowest group, the OTM+ADSCs+PPP group, with a CEJ-ABC distance of 0.96±0.08mm ( Fig.10 b).
[0080] 2.6.3 Micro-CT scanning of alveolar bone related parameters
[0081] The BV / TV value is the bone volume fraction, and the present invention selects ROI as the same volume, that is, the TV value is constant, which can reflect the change in the bone volume of the region of interest above the threshold. 4 weeks after injection, the BV / TV value of the OTM+ADSCs+PPP group was the highest at 98.96±0.25%, followed by the OTM+ADSCs group value of 95.91±1.38%, the CON group value of 94.91±1.36%, there was no statistical difference between the three, the OTM+PPP group value was lower at 71.52±10.19%, and the OTM group value was the lowest at 60.02±7.59%, there was no statistical difference between the two, but there was a significant statistical difference with the first three groups (P<0.005). 8 weeks after injection, the BV / TV value change trend of each group was similar to that 4 weeks after injection, the OTM+ADSCs+PPP group value was the highest at 95.40±6.23%, and the lowest was 70.74±13.68% in the OTM group. Therefore, the bone volume decreased and bone mass was lost in the OTM group and OTM+PPP group, while the bone volume increased and bone mass was gained in the OTM+ADSCs group and OTM+ADSCs+PPP group.
[0082] TB.N is the number of trabeculae, and the highest value in the OTM+ADSCs+PPP group was 2.24±0.01mm at 4 weeks after injection. -1 The lowest value of OTM group was 1.48±0.15mm -1 There was a significant statistical difference compared with the CON group (P < 0.005), while there was no statistical difference between the OTM + PPP group and the OTM + ADSCs + PPP group. 8 weeks after injection, the TB.N change trend of each group was similar to that of 4 weeks after injection, and the highest value of the OTM + ADSCs + PPP group was 1.85 ± 0.14 mm -1 The lowest value of OTM group was 1.58±0.19mm -1 However, only the OTM group showed statistically significant differences compared with the CON group (P < 0.05). It can be seen that the number of trabeculae in the OTM group decreased significantly, while the number of trabeculae in the OTM+ADSCs+PPP group increased, while the number of trabeculae in the OTM+PPP group and the OTM+ADSCs group remained basically unchanged.
[0083] Tb.Th is the thickness of trabecular bone. The highest value of OTM+ADSCs group was 0.51±0.01mm at 4 weeks after injection, and the lowest value of OTM+PPP group was 0.37±0.04mm. Compared with CON group, all groups except OTM+ADSCs group showed statistical differences (P<0.05). 8 weeks after injection, the change trend of Tb.Th in each group was similar to that at 4 weeks after injection. The highest value of OTM+ADSCs+PPP group was 0.56±0.05mm, and the lowest value of OTM+PPP group was 0.44±0.01mm. However, only OTM+ADSCs group showed statistical differences compared with CON group (P<0.005). Therefore, the trabecular bone thickness of OTM+ADSCs group increased slightly, and the trabecular bone thickness of other groups decreased significantly.
[0084] Tb.Sp is the trabecular space. The highest value in the OTM group was 0.22±0.03mm at 4 weeks after injection, which was statistically significant compared with the other groups. The second highest value was 0.16±0.05mm in the OTM+PPP group, followed by the OTM+ADSCs group, the CON group, and finally the OTM+ADSCs+PPP group, which was 0.04±0.01mm. However, there was no statistical difference among the latter three groups. At 8 weeks after injection, the highest value was 0.17±0.07mm in the OTM group, and the lowest value was 0.08±0.01mm in the CON group. However, there was no statistical difference among the groups ( Fig.11 ). It can be seen that the trabecular gaps in the OTM group and the OTM+PPP group increased significantly, while the trabecular gaps in the OTM+ADSCs group and the OTM+ADSCs+PPP group remained basically unchanged or even decreased.
[0085] 2.6.4 HE staining to observe the tissue morphology of the applied area and Trap staining to detect the number of osteoclasts
[0086] The first molar was sectioned along the mesiodistal direction, and the area selected was the distal area of the mesial root of the first molar, that is, the tension area generated after the tooth was stressed was observed. By HE detection of histological changes, clear periodontal tissue structures were visible in the CON group: tooth roots, periodontal ligament, and alveolar bone, among which the periodontal ligament had a regular wavy shape. In the other groups, after orthodontic force was applied, the periodontal ligament gaps increased, the periodontal ligament lost its typical wavy arrangement, and the periodontal fibers were stretched between the root and the alveolar bone. Four weeks after injection, compared with the OTM group, the periodontal fibers in the OTM+PPP group were stretched to a greater extent, while bone islands and new alveolar bone were visible in the OTM+ADSCs group and the OTM+ADSCs+PPP group, but there were gaps between the bones. After another 4 weeks and 8 weeks after injection, the periodontal fibers in each group basically returned to the wavy shape of the CON group, and the gaps between the bones in the OTM+ADSCs group and the OTM+ADSCs+PPP group disappeared and were replaced by a large amount of alveolar bone, forming a dense periodontal tissue ( Fig.12 a).
[0087] The number of osteoclasts was detected by Trap staining, and osteoclasts were stained pink. A small number of stained osteoclasts were observed in the distal periodontal ligament of the CON group, while no obvious stained osteoclasts were observed in the OTM+PPP group. In the other groups, stained osteoclasts were observed at the critical position between the periodontal ligament cells and the alveolar bone ( Fig.12 b).
[0088] Osteoclast counting and detection showed that 4 weeks after injection, the number of osteoclasts in the OTM+ADSCs+PPP group and the OTM+ADSCs group on the tension side of the mesial root of the first molar increased significantly, while the number of osteoclasts in the OTM group and the OTM+PPP group decreased, which was statistically different from the CON group (P < 0.05). 8 weeks after injection, the number of osteoclasts in the OTM+ADSCs+PPP group was the highest, and the number of osteoclasts in the OTM+PPP group was the lowest, which was statistically different (P < 0.05), but the number of osteoclasts was significantly reduced compared with the OTM+ADSCs+PPP group and the OTM+ADSCs group 4 weeks after injection. Therefore, the osteoclast activity of the OTM+ADSCs+PPP group and the OTM+ADSCs group increased significantly 4 weeks after injection, while the osteoclast activity of the OTM+PPP group decreased significantly. However, 8 weeks after injection, the osteoclast activity of the OTM+ADSCs+PPP group and the OTM+ADSCs group decreased, and the osteoclast activity of the OTM+PPP group increased ( Fig.12 c).
[0089] 2.6.5 RANKL and OPG immunohistochemistry results
[0090] Immunohistochemistry was used to detect the expression of RANKL osteogenic-related factors and OPG osteoclastogenic-related factors, and the effect of combined use of ADSCs and PPP on bone remodeling was further evaluated. The cell membrane was stained brown by RANKL immunohistochemistry, that is, the membrane was positive. Positive cells were found in the periodontal ligament of the CON group, OTM group, and OTM+PPP group, while a large number of positive cells were found in the alveolar bone of the OTM+ADSCs group and OTM+ADSCs+PPP group. The cell nucleus was stained brown by OPG immunohistochemistry, that is, the nucleus was positive. Positive cells were found in the periodontal ligament and alveolar bone in each group ( Fig.13 a, b).
[0091] Quantitative analysis of RANKL osteogenic factor was performed. After 4 weeks of injection, compared with the CON group, the expression levels of the OTM group, OTM+PPP group, and OTM+ADSCs group increased in turn, with no statistical difference, but the expression level of the OTM+ADSCs+PPP group was the highest, with a significant statistical difference (P < 0.005). After 8 weeks of injection, compared with the CON group, the expression levels of the other groups decreased, with statistical differences (P < 0.05), but there was no statistical difference between the groups ( Fig.13 c). Therefore, 4 weeks after injection, the activity of osteogenic factors in the OTM+ADSCs group and the OTM+ADSCs+PPP group increased significantly, while 8 weeks after injection, the expression of osteogenic factors in these two groups tended to stabilize and returned to the level of the other groups.
[0092] Quantitative analysis of OPG osteoclastogen was performed. After 4 weeks of injection, the expression levels of CON group, OTM+PPP group, OTM+ADSCs+PPP group, OTM+ADSCs group, and OTM group increased in turn. Compared with the OTM group with the highest expression level, the CON group and the OTM+PPP group had statistical differences (P<0.05), and there was no statistical difference compared with the other two groups. After 8 weeks of injection, except for the CON group, the expression levels of the other groups decreased, and the expression levels of the OTM+ADSCs group and the OTM+ADSCs+PPP group decreased significantly, with significant statistical differences (P<0.005) ( Fig.13 c). Therefore, 4 weeks after injection, the osteoclasts in the OTM group, OTM+ADSCs group, and OTM+ADSCs+PPP group were actively expressed, but 8 weeks after injection, the osteoclasts in the OTM+ADSCs group and OTM+ADSCs+PPP group decreased significantly.
[0093] By comparing the RANKL / OPG ratio, we detected whether osteoblasts or osteoclasts were dominant in the bone remodeling process. After 4 weeks of injection, the RANKL / OPG ratio in the OTM+ADSCs+PPP group was the highest at 1.54±0.47, while the value in the OTM group was the lowest at 0.52±0.13, with significant statistical difference (P<0.01). Compared with the CON group, the values of the OTM+PPP group, OTM+ADSCs group, and OTM+ADSCs+PPP group increased in turn, while the value of the OTM group decreased ( Fig.13 c). After 8 weeks of injection, the RANKL / OPG ratio in the OTM+ADSCs group was the highest at 1.59±0.26, and the OTM group had the lowest value at 0.96±0.15, with significant statistical difference (P<0.01). Compared with the CON group, the values of the OTM+ADSCs group and the OTM+ADSCs+PPP group increased, while the values of the OTM+PPP group and the OTM group decreased. Therefore, after 4 and 8 weeks of injection, the OTM+ADSCs group and the OTM+ADSCs+PPP group showed osteogenic advantage, while the OTM group showed osteoclast advantage, and the OTM+PPP group showed osteogenic advantage after 4 weeks of injection, while it showed osteoclast advantage after 8 weeks.
[0094] The above is an explanation of the embodiments of the present invention. However, the present invention is not limited to the above embodiments. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A composition containing adipose-derived stem cells (ADSCs), further comprising any one of platelet-poor plasma (PPP), platelet-rich plasma (PRP), or platelet lysate (PL).
2. The composition according to claim 1, characterized in that The adipose stem cells are human adipose stem cells, canine adipose stem cells or mouse adipose stem cells.
3. The composition according to claim 2, characterized in that The human adipose stem cells are human subcutaneous tissue adipose stem cells, intraperitoneal region adipose stem cells and organ surface adipose stem cells.
4. The composition according to claim 1, characterized in that The platelet-poor plasma is human platelet-poor plasma or rat platelet-poor plasma.
5. The composition according to claim 1, characterized in that The platelet-rich plasma is human platelet-rich plasma or rat platelet-rich plasma.
6. The composition according to claim 1, characterized in that The platelet lysate is human platelet lysate or rat platelet lysate.
7. The composition according to any one of claims 1 to 6, characterized in that The composition also includes a pharmaceutically acceptable carrier or excipient; the pharmaceutically acceptable carrier or excipient is selected from at least one of the following: glycerol, sorbitol, sodium carboxymethyl cellulose, xanthan gum, carrageenan, polyethylene glycol, sodium pyrophosphate, sodium lauryl sulfate, allantoin, sodium saccharin, sodium benzoate, ethyl paraben, calcium carbonate, calcium hydrogen phosphate dihydrate, calcium hydrogen phosphate anhydrous, silicon dioxide, hydroxyapatite, dipotassium glycyrrhizinate, and flavor.
8. The composition according to claim 7, characterized in that The injection preparations were prepared by resuspending ADSCs in PPP, PRP or PL.
9. The composition according to claim 8, characterized in that Each 0.3 ml of PPP, PRP or PL contains 1x10 5 ~1x10 7 ADSCs.
10. Use of the composition according to any one of claims 1 to 9 in the preparation of a medicament for accelerating orthodontic tooth movement and bone remodeling.
